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Silver nanoparticles (AgNP), the most popular nano-compounds, possess unique chemical, physical 
and biological properties. Albizia adianthifolia (AA) – rich in saponins – is a plant of the Fabaceae 
family, found abundantly on the East coast of Africa. This plant is well known for its medicinal 
properties, and although the exact phytochemistry of AA is unknown, recent research suggests that 
AA can be used for the treatment of certain pathologies. The biological properties of a novel silver 
nanoparticle (AAAgNP) synthesised from an aqueous leaf extract of AA, were investigated on A549 
lung carcinoma cells. Cell viability was determined by the 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide assay. Cellular oxidative status (lipid peroxidation and 
glutathione (GSH) levels) were determined by the TBARS and GSH-Glo™ Glutatione assays 
respectively. ATP concentration was measured using the CellTitre-Glo
™
 assay. Caspase-3/-7, -8 
and -9 activities were determined by Caspase-Glo
®
 assays. Flow cytometry was used to measure 
apoptosis, mitochondrial (mt) membrane depolarisation, expression of CD95 receptors and 
intracellular smac/DIABLO levels. DNA fragmentation was assessed with the comet assay. The 
expression of p53, bax, PARP-1 and smac/DIABLO was evaluated by western blotting. 
Quantitative polymerase chain reaction was used to determine mRNA levels of bax and p53. 
AAAgNP caused a dose-dependent decrease in cell viability with a significant increase in lipid 
peroxidation (5-fold vs. control; p=0.0098) and decreased intracellular GSH (p=0.1184). A 
significant 2.5-fold decrease in cellular ATP was observed upon AAAgNP exposure (p=0.0040) with 
a highly significant elevation in mt membrane depolarisation (3.3-fold vs. control; p<0.0001). 
Apoptosis was also significantly higher (1.5-fold) in AAAgNP treated cells (p<0.0001) with a 
significant decline in expression of CD95 receptors (p=0.0416). AAAgNP caused a significant 2.5-
fold reduction in caspase-8 activity (p=0.0024) with contrasting increases in caspase-3/-7 (1.7-fold 
vs. control; p=0.0180) and -9 activity (1.4-fold vs. control; p=0.0117). Western blots showed 
increased expression of smac/DIABLO (4.1-fold) in treated cells (p=0.0033). Furthermore, AAAgNP 
significantly increased the expression of p53, bax cleaved PARP-1 (1.2-fold; p=0.0498, 1.6-fold; 
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p=0.0083 and 1.1-fold; p=0.0359 respectively). The expression of mRNA for both p53 and bax was 
also elevated post AAAgNP treatment, with 6-fold (p=0.0036) and 5-fold (p=0.0080) changes 
respectively compared to untreated cells. Data suggests that AAAgNP induces cell death in the A549 
lung cells via the mt-mediated intrinsic apoptotic program. Further investigations are required to 
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Nanotechnology is a rapidly expanding branch of modern technology. Nanoparticles (NPs) are 
commonly defined as small sized (1-100nm) compounds that are able to function as whole units. 
These compounds are becoming widespread for their use in consumer products and medical 
applications; with prospective for utilization as therapeutic compounds, transfection vectors, anti-
microbial agents and fluorescent labels (Su et al., 2008). Silver nanoparticles (AgNP) are the most 
commercialised and prominent group of nano-compounds, attributed to their diverse applications in 
the health sector.  
Cancer is one of the leading causes of global morbidity and mortality. It is estimated that the world 
cancer burden will increase by 50% in the next 20 years (Bello et al., 2011). The South African 
Medical Research Council ranked cancer as the fourth leading cause of death in South Africa (SA) 
in 2003; in 2006 alone, there were 4525 deaths due to lung cancer in SA (Bello et al., 2011). As 
much as 80-90% of lung cancer cases are attributed to smoking, with the smaller proportion (10-
20%) as a result of occupational exposure to heavy metals and other toxic compounds (Siemiatycki 
et al., 2004; Driscoll et al., 2005). Recently, an association has been found between the acquired 
immunodeficiency syndrome (AIDS) and the development of lung cancer (Long et al., 2008). This 
is of great concern in view of the AIDS crisis in SA. The financial strain of anti-retroviral (ARV) 
treatment and cancer therapy on the health system in SA necessitates the need for alternate means 
of medication that is cost effective, easily accessible and safe.  
Silver (Ag) is known to possess unique and unusual chemical, physical as well as biological 
properties (Moaddab et al., 2011). Since the introduction of Ag as a colloidal form in the 1990s, 
immense progress has been made regarding the usage of Ag for treatment of bacterial infections in 
open wounds, with Ag based ointments, bandages and wound dressings being readily available in 
the present age (Arora et al., 2008). Also, nanosilver has been used as a contraceptive and a water 
disinfectant (Hansen et al., 2008; Madhumathi et al., 2010). 
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The use of AgNPs as anti-cancer agents has proved promising in research, creating new avenues for 
therapeutic intervention in the field of oncology (Moaddab et al., 2011). Various attempts to 
incorporate AgNPs into cancer treatments have been made, with positive outcomes (Vaidyanathan 
et al., 2009). Although the induction of oxidative stress by AgNP induced mitochondrial (mt) 
damage has been observed as the general mode of AgNP toxicity, mechanistic pathways remain 
unclear (Foldbjerg et al., 2011).  
Albizia adianthifolia (AA), also known as ‘Flatcrown’ or ‘Rough-barked flat-top’, is a plant 
member of the Fabaceae family found abundantly on the east coast of SA. This plant contains 
saponins such as prosapogenins and triterpene saponins (Lacaille-Dubois, 2000; Haddad et al., 
2004). Saponins are plant glycosides that possess significant anti-cancer properties (Man et al., 
2010). The isolated biological properties of Ag and AA were considered for the synthesis of a novel 
NP (AAAgNP). This study sought to determine the anti-cancer properties of AAAgNP conjugated to 
leaf extracts of the plant. 
Originating from human lung carcinoma, A549 cells belong to the most well-characterised and 
extensively used in vitro model. The A549 cell line has been used frequently to study nanotoxocity 
and nanoparticle interactions (Sahu and Casciano, 2009). It was hypothesised that AAAgNP induced 
apoptotic death in the cancerous lung cells by AAAgNP mediated increased generation of reactive 





1 LITERATURE REVIEW 
1.1 Nanosilver: emerging benefits in the medical sector 
The vast extension of nanoscience has resulted in a large scale escalation in consumer products 
that contain nano-compounds. Nanotechnology is a burgeoning field, offering benefits in 
healthcare with endless interventions. Silver nanoparticles are the most commercialised group of 
nano-compounds in the current generation. Skin creams, wound dressings, catheter tubes and 
bone cements are but a few of a long list of medical necessities being manufactured containing 
AgNPs. Diagnostics have subjugated nanoparticles as imaging contrast agents. Furthermore, the 
performance of surgical tools and the biocompatibility of tissue and organ implants have been 
enhanced by nanostructured surface modifications (Sahu and Casciano, 2009).  
The revolutionary notion that AgNPs can be used to improve the way diseases are treated is now 
being exploited, affording potential in the treatment of ailments such as retinal 
neurovascularisation (Bhattacharya and Mukherjee, 2008; Kalishwaralal et al., 2010) and AIDS 
as a result of human immunodeficiency virus (HIV) infection (Sun et al., 2005; Lara et al., 
2010). Silver nanoparticles are well known for their anti-microbial properties and are used as 
antiviral agents against hepatitis B, herpes simplex virus type 1, monkey pox virus and 
respiratory syncytial virus (Lu et al., 2008; Rogers, 2008; Sun, 2008; Baram-Pinto et al., 2009).  
Silver nanoparticles have also proved promising in cancer therapy. Silver oxide NPs were shown 
to possess anti-tumour properties in transplanted Pliss lymphosarcoma tumour models upon 
intravenous administration (Rutberg et al., 2008). In a study using bovine retinal endothelial 
cells, AgNPs were found to inhibit vascular endothelial growth factor (VEGF) induced 
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angiogenesis (Kalishwaralal et al., 2009). Silver nanoparticles induced tumour inhibitory effects 
on Dalton’s lymphoma ascites (DLA) cells as well as on Swiss albino mice, without toxicity to 
normal cells (Sriram et al., 2010). Sriram et al. (2010) further elucidated that the mechanism by 
which AgNPs exerted cytotoxic effects on the DLA tumour cell line was by the induction of 
apoptosis as a result of caspase-3 activation (Sriram et al., 2010). Silver nanoparticles have been 
synthesised with a wide range of compounds that have valuable medicinal properties. 
1.2 Albizia adianthifolia: potential in cancer therapy 
The Albizia genus is comprised of about 150 species that are largely distributed in the tropics. 
The greatest diversity of these plants is in Africa and Central/South America (Abdel-Kader et al., 
2001). Albizia adianthifolia (Figure 1) is one species that is easily cultivated and found in excess 
in SA. This species is used in parts of Africa for the treatment of bronchitis, headaches, skin 
diseases, tapeworm, sinusitis, typhoid fever, inflamed eyes and urinary and respiratory infections 
(Tamokou Jde et al., 2012). These plants are well known for their constituent alkaloids, steroids, 
triterpenoid saponins and flavonols all of which possess medicinal value (Haddad et al., 2003). 
Saponins from AA, in particular, have received much attention for the wide range of properties 




Figure 1: Illustration of the tree, leaves and flowers of Albizia adianthifolia.  
Saponins, produced primarily by plants, are bioactive glycosides that have various biological and 
pharmacological properties (Figure 2). Saponins are grouped chemically into steroid or 
polycyclic triterpene saponins (Kensil, 1996). Some of the well characterised and significant 
biological actions of saponins include; cell membrane permeabilisation (Hostettmann and 
Martson, 1995), sequestering of serum cholesterol (Francis et al., 2002), stimulation of 
luteinising hormone release (Francis et al., 2002), toxicity enhancement of immunotoxins 
(Bachran et al., 2008b), immuno-modulation via cytokine interplay (Sun et al., 2009) and 




Figure 2: The biological functions of saponins. 
In 1960, the very first investigation on the use of saponins for the treatment of tumours was 
documented (Friess et al., 1960). To date, over 1200 studies (Pubmed search: “cancer”, 
“saponins”) on the ability of saponins to inhibit tumour growth or induce apoptosis have been 
reported. Saponins are used successfully in combination with chemotherapeutic agents for the 
enhancement of drugs in tumour treatment as well as to enhance membrane transportation 
(Mayank et al., 2011). The delivery of drugs to target cells in cancer therapy is a vital 
consideration. Extensive studies were conducted to determine if saponins could selectively aid 
drug delivery to cancer cells. Cisplatin, for example, used in combination with saponins isolated 
from AA possesses potent anti-tumour properties (Haddad et al., 2003; Haddad et al., 2004). In 
an investigation in 2001, triterpene saponins exhibited selective inhibition of tumourigenesis by 
inducing cell cycle arrest in a human breast cancer cell line and initiation of apoptosis in a 
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leukemia cell line (Mujoo et al., 2001). Haddad et al. (2004) investigated the biological 
properties of triterpene saponins (Figure 3) extracted from the root of AA on leukemic cells in 
vitro (Jurkats cells). They reported that the saponins exhibited a cytotoxic effect and induced 
apoptosis (Haddad et al., 2004). These properties make AA an ideal plant for the isolation of 
active compounds against cancer. Although, the exact phytochemistry of the plant still needs to 
be elucidated.  
 
Figure 3: Biochemical structure of a triterprene saponin isolated from Albizia adianthifolia 
(Mayank et al., 2011). Copyright permission for reproduction was granted from the author. 
1.3  Apoptosis:  a programmed cell death 
Regulation in the number of cells in multicellular organisms is an important process. Each day, 
billions of cells are subjected to an altruistic death in order to maintain functionality of the 
organism as a whole (Fischer and Schulze-Osthoff, 2005). Characterised by distinct 
morphological changes, apoptosis involves a series of precisely regulated events that lead to cell 
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destruction and disintegration. A group of aspartate-specific cysteinyl proteases referred to as 
caspases are the executioners of- and form the engine of apoptosis. Categorised into two distinct 
groups, initiator or activator caspases are responsible for proteolytic cleavage and subsequent 
activation of the second group of caspases, the executioners or effectors (Fischer and Schulze-
Osthoff, 2005). All caspase enzymes contain an active-site cysteine and are known to cleave 
substrates that possess aspartate residues. Over twelve caspases have been discovered in humans 
thus far, of which two thirds have been implicated in apoptotic cell death (Thornberry and 
Lazebnik, 1998; Earnshaw et al., 1999). Caspases are synthesised as inactive zymogens that are 
made up of three domains: a prodomain at the N-terminus, a p20 and a p10 domain both found in 
a mature caspase. For activation of caspases, the zymogen must usually undergo cleavage 
between p20 and p10 domains or between the prodomain and the p20 domain. Executioner 
caspase are functional in inflicting morphological changes of apoptosis-undergoing cells; cell 
shrinkage, hypercondensation of chromatin, chromosomal cleavage into nucleosomal fragments, 
blebbing of plasma membrane and packaging of cellular contents into apoptotic bodies – 
membrane enclosed vesicles (Hengartner, 2000). Two major apoptotic pathways exist in 
mammalian cells: the extrinsic death receptor-mediated and intrinsic mt-mediated pathways 
(Figure 3). Both pathways are tightly regulated and controlled by a host of regulatory molecules, 
some of which are highlighted further on. 
1.3.1 The extrinsic apoptotic program: death receptor pathway 
The extrinsic pathway of apoptosis involves transmembrane death receptor-mediated reactions. 
The best documented and characterised mechanism for caspase activation via the extrinsic 
pathway involves the tumour necrosis factor (TNF)-α family of death receptors. These include 
TNF-α receptor 1 (TNF-R1), TNF-related apoptosis-inducing ligand (TRAIL)-R1/R2, Fas 
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(CD95)-R, DR3 and CAR-1 all known to transduce apoptotic signals (Reed, 1999). Receptors of 
the TNF-α family share a common cysteine rich extracellular domain, with a cytoplasmic 
domain known as the death domain (DD) (Ashkenazi and Dixit, 1998). The role of these DDs is 
significant in the transmission of death signals from the outer cell surface to intracellular 
signalling pathways. Downstream events that define the extrinsic program of apoptosis following 
ligand-receptor binding have been most extensively characterised with TNF/TNF-R and Fas-
ligand (Fas-L)/Fas-receptor (Fas-R) models (Chicheportiche et al., 1997; Ashkenazi and Dixit, 
1998; Peter and Krammer, 1998; Suliman et al., 2001; Rubio-Moscardo et al., 2005). A 
clustering of death receptors is seen on the membrane with subsequent binding and attachment of 
homologous trimeric ligands. Cytoplasmic adaptor proteins that present with corresponding DDs 
for binding to death receptors are then recruited. Fas-L/Fas-R recruits Fas associated protein with 
DD (FADD) whereas TNF/TNF-R recruits TNF-R1 associated protein with DD (TRADD) with 
FADD and RIP (Hsu et al., 1995; Wajant, 2002). FADD contains an additional domain known as 
the death effector domain (DED). Via dimerisation of the DED, FADD associates with 
procaspase-8 and which contains a homologous DED. A death inducing signalling complex 
(DISC) is then formed, resulting in the auto-catalytic cleavage and activation of caspase-8 
(Kischkel et al., 1995). The execution phase of apoptosis is administered upon caspase-8 
activation, with the cleavage of procaspase-3 and -7. Research has revealed that a protein called 
cellular flice inhibitory protein (c-FLIP) inhibits death receptor-mediated apoptosis by binding to 




Figure 4: Overview of the extrinsic and intrinsic apoptotic pathways (Hengartner, 2000). 
Copyright permission for reproduction was granted from the author. 
1.3.2 The intrinsic apoptotic program: mitochondrial-mediated pathway 
Independent of receptor-mediated stimuli, the intrinsic pathway of apoptosis is controlled by 
stimuli that produce intracellular signals to directly target molecules within the cell, and is 
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mediated by the mt. Such stimuli induce changes to the inner mt membrane. A crucial step for 
the release of mt apoptotic proteins is the permeabilisation of the mt membrane. The Bcl-2 
family of proteins is involved in the control of mt permeabilisation during apoptosis (Lalier et 
al., 2007). Bax is one proapoptotic protein of the Bcl-2 family. Two conformational states of bax 
are present in cells: 1) cytosolic native bax and 2) activated bax associated with mt membrane 
permeabilisation. The switch from native to activated bax occurs during apoptosis. Oligomerised 
bax forms mt membrane permeability transition (PT) pores, loss of mt membrane potential with 
subsequent intermembrane release of two main groups of apoptogenic molecules into the cytosol 
(Wang, 2001; Saelens et al., 2004). Cytochrome c, second mitochondria-derived activator of 
caspases (smac)/DIABLO, and the serine protease HtrA2/Omi belong to the first group. This 
group of proteins brings about the activation of the caspase-dependent mt pathway (Elmore, 
2007). An apoptosome is formed with cytochrome c, apoptotic protease activating factor (Apaf)-
1 and procaspase-9. The oligomerisation of procaspase-9 in apoptosome formation results in the 
activation of caspase-9 which in turn activates the executioner caspases. Smac/DIABLO and 
HtrA2/Omi promote apoptosis by impeding the activity of inhibitor of apoptosis proteins (IAP) 
(van Loo et al., 2002; Schimmer, 2004). The second group of pro-apoptotic proteins includes 
caspase activated DNase (CAD), apoptosis inducing factor (AIF) and endonuclease G. The 
release of these proteins from the mt is a late event and occurs after the onset of apoptosis. 
Apoptosis inducing factor induces DNA fragmentation and condensation of peripheral nuclear 
chromatin after being translocated to the nucleus (Joza et al., 2001). Endonuclease G produces 
oligonucleosomal DNA fragments as a result of cleavage of nuclear chromatin (Li et al., 2001). 
Caspase activated DNase, whose cleavage and activity is dependent on caspase-3, also results in 
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oligonucleosomal DNA fragmentation but with more pronounced and advanced condensation of 
chromatin (Enari et al., 1998). 
1.3.3 Executioner caspases and the inhibition of poly (ADP-ribose) polymerase-1  activity 
The intrinsic and extrinsic pathways both converge at the activation of executioner caspases. 
Caspases-3 and -7 are responsible for the activation of cytoplasmic endonucleases (which 
degrade nuclear material) and proteases (which degrade cytoskeletal and nuclear proteins). Of 
the executioner caspases, caspase-3 is considered the most important (Elmore, 2007). Caspase 
activated DNase is an endonuclease that is specifically activated by caspase-3. Caspase activated 
DNase is complexed with an inhibitor ICAD in normal proliferating cells, but, caspase-3 cleaves 
ICAD to release CAD in apoptotic cells (Sakahira et al., 1998). Additionally, caspase-3 is 
instrumental in the disintegration of cells into apoptotic bodies by cytoskeletal reorganisation.  
Another significant function of caspase-3 is the cleavage of poly (ADP-ribose) polymerase 
(PARP)-1. In response to DNA damage, the process of poly-ADP-ribosylation is vital for 
genomic maintenance (D'Amours et al., 2001). Poly (ADP-ribose) polymerase -1 is responsible 
for this process, and is known to be a key regulator of the DNA base excision repair system (de 
Murcia et al., 1997; Trucco et al., 1998; d'Adda di Fagagna et al., 1999; Vodenicharov et al., 
2000). The activation of PARP-1 is also implicated in the regulation of transcription, DNA 
replication, protein degradation and cytoskeletal organisation (Hong et al., 2004). In apoptosis 





Figure 5: Fate of PARP-1 during apoptosis. 
1.3.4 Inhibitor of apoptosis proteins  
Amongst various molecules that are involved in the regulation of apoptosis, inhibitor of 
apoptosis proteins (IAPs) represent a group of proteins that serve as major control factors in the 
execution of cell death. Inhibitor of apoptosis proteins are characterised by a shared conserved 
sequence, the baculoviral IAP repeat (BIR) at the N-terminus and a conservative C-terminal 
really interesting new gene (RING) domain (Salvesen and Duckett, 2002). Baculoviral IAP 
repeat domains are 70 amino acid zinc-finger like structures that are essential for the anti-
apoptotic functions of IAPs. These zinc fingers are able to bind to the surface of caspases such 
that amino acid linker sequences between BIR regions block the catalytic sites of caspases (Fan 
et al., 2005). One or more (up to three) BIR domains may be contained within IAPs (Chai et al., 
2000). In humans, the following are some of IAP members that have been identified: cIAP1, 
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cIAP2, X-linked mammalian (X)-IAP, neuronal apoptosis inhibitory protein (NAIP), survivin 
and livin (Fan et al., 2005).    
Inhibitor of apoptosis protein molecules function as endogenous inhibitors of caspase activity, 
the main executioners of programmed cell death (Fan et al., 2005). The mt- and death receptor-
mediated programs of apoptosis both converge on the activation of executioner caspases. Studies 
have revealed more than one mechanism by which IAPs inhibit caspase activity; 1) the 
association of the IAP-BIR domain with the active sites of caspases, rendering them inactive, 2) 
IAP mediated degradation of active caspases and 3) the sequestering of caspases, by IAPs, away 
from their substrates (Wei et al., 2008). Different IAPs, in mammals, regulate caspase activity in 
various ways. Additionally, different BIR domains even within the same IAP molecule execute 
different caspase-inhibitory functions. For instance, in the death receptor-mediated apoptotic 
pathway, IAPs are not bound to caspase-8; rather, they inhibit its substrate – caspase-3. On the 
other hand, there are three ways by which IAPs execute their caspase suppression roles in the mt-
mediated apoptotic pathway; 1) by competitively binding procaspase-9 and thus interfering with 
apoptosome formation between procaspase-9 and Apaf-1, 2) directly binding to caspase-9 and -
3) directly binding to caspase-3 (Cheung et al., 2006).  
X-linked mammalian IAP is recognized as the most well characterised IAP molecule and potent 
endogenous caspase inhibitor. This IAP contains three BIR regions namely BIR1, BIR2, and 
BIR3, each with high affinity for caspases but with varying functions. The BIR2 region and the 
linker area between BIR1 and BIR2 domains are known to specifically bind to and inhibit 
caspases-3 and -7. Specifically, the BIR2 region associates across the catalytic site of caspase-3, 
blocking the substrate binding pocket and thus inhibiting the activity of caspase-3. The BIR3 and 
RING domains are required for the inhibition of caspase-9. Inhibition of caspase-9, unlike that of 
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caspase-3, doesn’t involve the binding of BIR domains to the active site. Rather, the BIR3 
domain associates with monomeric procaspase-9 forming a heterodimer, preventing the 
dimerisation of procaspase-9 and activation of caspase-9 thereafter.  
1.3.5 Smac/DIABLO 
Smac/DIABLO is a proapoptotic protein that is released from the mt, during apoptosis, into the 
cytosol. The function of smac/DIABLO, as discussed earlier, is to promote the activation of 
caspases by competitively binding to IAP molecules, thus relieving caspases from the inhibitory 
effects of IAPs (Figure 6). Smac/DIABLO is synthesised with a 55 amino acid mt targeting 
sequence at the N-terminus. In a mature smac/DIABLO, the first four amino acids are crucial for 
their interaction with IAPs. The amino acids Ala-Val-Pro-Ile (AVPI) bind with BIR domains of 
IAPs (Chai et al., 2000). Alanine only becomes exposed once the signal sequence has been 
removed following mt entry. As a result, mt targeting becomes a vital step in the functioning of 
smac/DIABLO. Furthermore, this strategy makes certain that smac/DIABLO does not execute 
premature apoptosis before its entry into the mt (Wu et al., 2000). 
The AVPI sequence of smac/DIABLO that binds to BIR3 domains of XIAP is much like the 
sequence of active caspase-9 to which XIAP binds (Ala-Thr-Pro-Phe). The IAP-binding region 
of caspase-9 is exposed only once procaspase-9 has been processed to its active form. Caspase-9 
activity is thus inhibited upon XIAP binding, but is neutralised when smac/DIABLO competes 
off caspase-9 (Srinivasula et al., 2001).  
It was also discovered that apart from the BIR3 domain of, smac/DIABLO can also form stable 
complexes with the BIR2 domain of XIAP (Chai et al., 2000). As mentioned earlier, the BIR2 
domain and the linker area between BIR1 and BIR2 domains bind to and inhibit caspases-3 and -
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7. Smac/DIABLO interacts with the BIR2 domain, hindering the XIAP inhibition of active 
caspases-3 and -7 sterically (Chai et al., 2000).  
 
Figure 6: Regulatory function of smac/DIABLO in apoptosis (Wang, 2001). Copyright 
permission for reproduction was granted from the author. 
The regulation between smac/DIABLO activation and IAP inhibition of caspases is an 
interesting one, suggesting a tightly controlled feedback system in cells. The release of 
cytochrome c from the mt results in apoptosome formation, upon associating with Apaf-1, with 
subsequent activation of caspase-9. However, this pathway is aborted when levels of IAP are 
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elevated. Inhibition of caspases by IAPs could be permanent as many IAPs contain a RING 
domain, which induces the proteosomal degradation of caspases (Yang et al., 2000; Suzuki et al., 
2001). This feedback mechanism ensures that in the event of incidental mt leakage of 
cytochrome c, IAPs are readily available to sequester apoptosome formation and prevent 
uncontrolled and inappropriate cell death. However, if damage to the mt is extensive such as in a 
pathological state, more smac/DAIBLO will be released from the mt to counteract the effects of 
IAPs (Wang, 2001). 
1.3.6 p53 and apoptosis 
The p53 (tumour suppressor/transcription factor) protein is an extensively studied protein. p53 is 
implicated in a variety of cellular processes, however, its function in cell cycle arrest and 
apoptosis has been well documented. A range of stimuli can activate p53: hypoxia, DNA 
damage, cellular senescence and apoptosis (Fridman and Lowe, 2003). The disruption of p53 
activity has been associated with genomic instability and the survival and proliferation of 
damaged cells. As such, it is not surprising that in human cancers, p53 is found most commonly 
dysregulated.  
A well known trait of p53 is its ability to regulate transcriptional activity of genes in apoptosis. 
p53 has been reported to directly activate genes that promote apoptosis (el-Deiry, 1998; Yu et al., 
1999; Sax and El-Deiry, 2003). The bax gene, for instance, harbours p53-binding spots in the 
promoter region and is thus upregulated in response to DNA damage and p53 (Miyashita and 
Reed, 1995). Members of a class of genes known as p53-induced genes (PIG) are involved in the 
induction of oxidative stress. p53-induced gene-3 was found to contain consensus p53 responsive 
elements for the binding of p53 in the promoter segment (Polyak et al., 1997).  
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1.4  Cancer cells evade apoptosis: promotion of tumourigenesis 
Apoptosis plays an integral role in homeostatic control of cell proliferation and death. On one 
hand, the regulation of development and generation of the immune system is dependent on 
apoptosis. On the other hand, dysregulation of apoptotic pathways could lead to severe 
pathological conditions.  
Cancer is a fatal outcome of disturbances in the apoptotic cascade. Particularly, incongruously 
low rates of apoptosis drive the proliferation of abnormal cells to form tumour masses. In this 
light, apoptosis is perceived as a ‘barrier’ to cancer (Hanahan and Weinberg, 2000). The ability 
of cancerous cells to evade apoptosis was first discovered during studies of follicular lymphoma, 
a cancer similar to Burkitt’s lymphoma. This disease is characterised by the chromosomal 
translocation of the immunoglobulin (Ig) heavy chain locus to chromosome 18 known as bcl-2. 
The over expression of this gene in B cells permitted their survival, even under conditions that 
would sequester normal cell proliferation and promote apoptosis (Vaux et al., 1988).  
Of the major external signals that trigger apoptosis, is Fas-L. Upon binding to its cognate 
receptor, Fas-receptor (CD95), the extrinsic apoptotic program is activated with the cleavage of 
procaspase-8 and activation of executioner caspases. The interaction between Fas-r/Fas-L and 
the respective signalling are thought to play a role in the pathology of carcinogenesis, the growth 
of tumours as well as metastasis (Owen-Schaub et al., 2000). Other members of membrane-
associated death receptors include TNF-α- and TRAIL-receptors, whose function is similar to 
that elicited by CD95 upon ligand binding. It was discovered, in the 1990s, that cancerous cells 
have developed a mechanism to evade apoptosis mediated by Fas and TRAIL. This involved the 
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synthesis, by cancer cells, of decoy receptors that upon ligand binding would not induce 
apoptosis (Pitti et al., 1998; Ashkenazi and Dixit, 1999; Marsters et al., 1999).  
Another strategy by which cancer cells acquire resistance to cell death is by a loss of function of 
the p53 tumour suppressor gene through a mutation (Hanahan and Weinberg, 2000). Functional 
inactivation of the p53 protein is seen in an excess of 50% of human cancers, resulting in the 
removal of one of the key components of the DNA damage sensory system that can initiate 
apoptosis (Harris, 1996). 
Inhibitor of apoptosis proteins are found to be over expressed in various cancers. Survivin is one 
IAP that is expressed at high levels in cancer cells compared to normal cells (Ambrosini et al., 
1997). Survivin is thought to play a role in cell division (Reed and Bischoff, 2000; Uren et al., 
2000), which could explain why their expression is high in actively dividing cancer cells as 











1.5  Drug intervention: induction of apoptosis in cancer 
A number of efforts have been made on the drug development frontier for the induction of 
apoptosis in tumour cells, some of which have proved beneficial. An in depth understanding of 
the apoptotic cascade under physiological as well as pathological conditions is essential for the 
development of apoptotic inducing/inhibiting drugs.  
In cancer, various approaches have been postulated with many drugs currently in preclinical 
trials. The activation of caspases, the chief executioners of apoptosis, in tumour cells is one such 
approach. Inducible caspases have been engineered by fusing them with chimeric dimerisation 
domains. Following delivery of these chimeric domains to tumour cells via adenoviral gene 
transfer, caspases may be triggered on demand to induce apoptosis (MacCorkle et al., 1998; 
Shariat et al., 2001). A report on the success of inducible caspase-9 in targeted prostate cancer 
cells in vitro was published (Xie et al., 2001). Prostrate tumour growth was suppressed just by 
simple intraperitoneal injection of the inducible caspase into mice, increasing survival.  
Inhibitor of apoptosis proteins are another target for apoptosis induction, considering their 
stringent regulatory attributes. Antisense strategies that target XIAP and survivin are presently in 
preclinical testing (Fischer and Schulze-Osthoff, 2005). Various antisense oligomeric nucleotides 
are constructed with short sequences that are complementary to the messenger ribonucleic acid 
(mRNA) of target IAP molecules. The hybridisation of antisense oligonucleotide constructs with 
target mRNA prevents the translation of mRNA. Additionally, it has been shown that enzymes 
such as RNase H target the mRNA/antisense oligonucleotide complex, degrading the mRNA 
freeing the antisense construct to target and bind to another mRNA strand (Fischer and Schulze-
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Osthoff, 2005). This strategy has been shown to sensitise a range of tumour cell lines to chemo- 
or radiotherapy (Holcik et al., 2000; Sasaki et al., 2000).  
As described previously, smac/DIABLO functions in antagonising the caspase-inhibitory effects 
of IAPs, making smac/DIABLO another target candidate for the promotion of apoptosis in 
cancer therapy. Smac peptides or smac mimetic drugs have been manufactured by companies for 
restoration of caspase activity; however, these approaches have not been successful when used as 
single agents (Fischer and Schulze-Osthoff, 2005). Nonetheless, smac peptides were found to 
sensitise cancerous cell lines as well as murine models of human glioma and lung cancer to 
chemotherapy (Arnt et al., 2002; Fulda et al., 2002; Guo et al., 2002; Tamm et al., 2003; Yang et 
al., 2003). Smac mimetic drugs synthesised from oxazoline were able to target XIAP, cIAP1 and 
cIAP2, with synergised effects upon TNF and TRAIL administration in cancer cell cultures (Li 
et al., 2004). Sun et al., in 2004, reported on a synthesised smac mimetic drug that bound XIAP 
and enhanced apoptosis induced by cisplatin in human prostate cancer cells with no effect when 
exposed to these cells alone (Sun et al., 2004).  
Various problems have been encountered with the use of smac mimetic drugs and peptides. For 
example, small smac peptides bind with less efficiency to XIAP compared to the wild type 
protein due to a difference in the length. The extent to which smac peptides interact with XIAP is 
not sufficient to relieve caspase-9. Some tumours express high levels of various isoforms of IAPs 
thus the inhibition of a single IAP isoform by drugs might be inadequate (Krajewska et al., 
2003).  
Although these few mentioned therapies may be of use in the near future, the cost factor may be 
prohibitive. Attention should be given to the development of safer and cheaper therapeutics that 
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are easily accessible. This study is a preliminary one that highlights the potential use of AAAgNP 
as an alternative for cancer therapy. 
1.6  Aims and objectives 
This study was conducted to determine the following: 
 The effect of AAAgNP on human lung carcinoma A549 cell viability. 
 The oxidative status of A549 cells exposed to AAAgNP. 
 The expression of selected apoptotic markers induced by AAAgNP in A549 cells. 














2 MATERIALS AND METHODS 
2.1  Materials 
The A549 cells were purchased from Highveld Biologicals (Johannesburg, SA). Cell culture 
reagents were purchased from Whitehead Scientific (Johannesburg, SA). LumiGLO
®
 
chemiluminescent substrate kit was purchased from Gaithersburg (United States of America 
(USA)) and western blot reagents were purchased from Bio-Rad (USA). All other reagents were 
purchased from Merck (South Africa). AAAgNP was obtained from Dr. Robert M. Gengan (Steve 
Biko campus), Durban University of Technology (DUT), Durban, SA. 
2.2  Synthesis and characterisation of AAAgNP 
The preparation and characterisation of AAAgNP was conducted by Dr. R.M Gengan, DUT. A 
one-pot green synthesis technique was used. Briefly, fresh leaves of AA were extracted, washed 
with deionised water and 20g of finely cut leaves were added to 200ml of deionised water. 
Leaves were boiled (15min) and the crude extract was filtered after cooling with Whatman no.1 
filter paper. The supernatant (1ml) was then allowed to react with 0.001 M silver nitrate 
(AgNO3) solution (49ml) at room temperature (RT). The AAAgNP solution (pH 7) was then 
characterised using UV spectrometry. Particle size was determined by transmission electron 
microscopy (TEM). To assess the interaction between nanosilver and compounds of the aqueous 
extracts of AA leaves, Fourier transform infrared (FTIR) spectrophotometry was employed 





2.3  Cell culture and exposure protocol 
The A549 cells were cultured in complete culture media (CCM) consisting of Eagle’s minimum 
essential medium supplemented with 1% L-glutamine, 1% penstrepfungizone and 10% foetal 
bovine serum. Cultures were maintained at 37°C with 5% CO2. For the 3-(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide or methylthiazol tetrazolium (MTT) assay, cells 
were seeded into a 96-well microtitre plate, allowed to attach overnight and treated with AAAgNP 
solution (0-75μg/ml) for 6h. For flow cytometry assays, caspase, ATP and lipid peroxidation 
assays, cells were cultured to 90% confluency in 25cm
2
 tissue flasks and treated with AAAgNP. 
For the GSH assay, cells were plated in 96-well microtitre plates and allowed to attach overnight, 
followed by treatment with AAAgNP. For western blot analysis, quantitative polymerase chain 
reaction (Q-PCR) and the comet assay, cells were grown to 90% confluency in 6-well culture 
plates and treated with AAAgNP.  
2.4  Cell viability  
2.4.1 MTT assay 
2.4.1.1  Introduction 
Cell viability was determined using the MTT assay. Methylthiazol tetrazolium is a yellow water 
soluble tetrazolium dye that when reduced by viable cells turns into a purple water insoluble 
formazan product. This reaction is dependent on the availability of cellular oxidoreductases, 
which are enzymes that catalyse the transfer of electrons from a reductant to an oxidant 




dinucleotide (FADH2) produced in the tricarboxylic acid (TCA) cycle are used as cofactors by 
oxidoreductases (Figure 7).  
 
Figure 7: The production of NADH and FADH2 in the TCA cycle for oxidative phosphorylation 
in the ETC for the generation of ATP. 
The functioning of oxidoreductases is therefore indicative of the metabolic activity, thus 
viability, of the cell. The intensity of the formazan produced is proportional to the metabolic 
activity within the cell.  
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2.4.1.2  Protocol 
For the MTT assay, approximately 20 000 cells (in six replicates) were used for exposure to 
AAAgNP concentrations in the treatment range (0-75μg/ml). After incubation with AAAgNP for 6h, 
cells were washed twice with 0.1M phosphate buffer saline (PBS) and incubated with MTT salt 
solution (5mg/ml in 0.1M PBS) and complete culture medium (37ºC, 4h). Thereafter, 100μl of 
dimethyl sulphoxide (DMSO) was added to each well and incubated (37ºC, 1h). The optical 
density of the formazan product was measured using a spectrophotometer (Bio-tek μQuant) at 
570/690nm. The results were expressed as percentage cell viability vs. concentration of AAAgNP, 














Figure 8: Schematic of the reduction of MTT salt to formazan by a viable cell. 
2.4.2 ATP ASSAY 
2.4.2.1  Introduction 
Cellular ATP production is an essential process of living organisms. The mt respiratory chain or 
electron transport chain (ETC) is most responsible for ATP production. Located in the inner mt 
membrane, the respiratory chain entails two synchronised processes; 1) the passage of electrons 
through the complexes to generate an electrochemical proton gradient and 2) the phosphorylation 




Figure 9: Illustration of the ETC located within the inner mitochondrial membrane.  
Oxidative phosphorylation, in the ETC, coupled to substrate level phosphorylation, in glycolysis 
and the TCA cycle, ensures the optimum production of ATP required by the cell for its 
sustenance and viability. Essential cofactors NADH and FADH2 are produced in the TCA cycle 
which feed into the ETC (Figure 7). 
 
2.4.2.2 Protocol 
To determine ATP concentration, the CellTire Glo
™
 (Promega) assay was used. Cells (20 
000/well) were alliquoted in an opaque microtitre plate to which the ATP CellTitre Glo
™
 reagent 
(50μl) was added and allowed to react in the dark (30min, RT). Following incubation, the 
luminescent signal proportional to the cellular ATP content was detected with a Modulus™ 
microplate luminometer (Turner Biosystems, Sunnyvale, USA). Results are expressed as mean 




Figure 10: Principle of the CellTire Glo
™ 




2.5  Oxidative stress 
2.5.1 Glutathione assay 
2.5.1.1  Introduction 
An excessive formation of ROS is cytotoxic. Therefore, systems that metabolise and scavenge 
ROS are functionally critical and tightly regulated in the cell. Glutathione is a low molecular 
weight, water soluble thiol that is found most abundantly in the cytosol of cells. Composed of the 
amino acids glycine, cysteine and glutamine, this anti-oxidant tripeptide plays an important role 
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in the detoxification of peroxides and electrophilic species (Townsend et al., 2003). Glutathione 
is able to effectively scavenge ROS such as hydrogen peroxide (H2O2), peroxynitrite as well as 
hydroxyl- and lipid peroxyl radicals (Wu et al., 2004). The thiol exists in an oxidized 
(glutathione disulphide (GSSG)) and a reduced (GSH) form in cells. Glutathione-S-transferase 
(GST) and glutathione peroxidase (GPx) are enzymes that catalyse the GSH-mediated 
detoxification of electrophilic compounds. Glutathione serves as the electron donor in a 
reduction reaction catalysed by GPx to detoxify peroxides (Figure 11).  
 
Figure 11: Detoxification of H2O2 by glutathione-S-transferase and the regeneration of 
glutathione from glutathione disulphide by peroxidase. 
 
2.5.1.2  Protocol 
The GSH-Glo™ Glutatione assay (Promega, Madison, USA) was utilized to quantify 
intracellular GSH levels. Subsequent to treatment of cells (10 000 cells/well in six replicates) in 
an opaque 96-well microtitre plate, culture medium was removed and 25µl of 1X GSH-Glo™ 
reagent (prepared according to manufacturer’s guidelines) was added to each well. GSH 
standards (0-5µM) were serially diluted (two-fold) from a 5mM stock in deionised water. After 
29 
 
brief mixing on a shaker and 30min incubation at RT, 100µl of Luciferin detection reagent was 
added to the wells (15min, RT). Luminescence was detected on a Modulus™ microplate 
luminometer (Turner Biosystems, Sunnyvale, USA). A standard curve was constructed and 
sample GSH concentrations (µM) were calculated. 
 
Figure 12: Schematic overview of the principle of the GSH-Glo™ Glutatione assay. 
 
2.5.2 Lipid peroxidation 
2.5.2.1  Introduction 
Lipid peroxidation is a process whereby lipids become oxidised, forming lipid peroxides as a 
result of free radical attack during oxidative stress. Polyunsaturated fatty acids (PUFAs) are most 
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susceptible to lipid peroxidation due to the presence of double bonds between adjacent carbon 
atoms (Figure 13).  
 
Figure 13: Chain reaction mechanism of lipid peroxidation. 
The chain reaction mechanism of lipid peroxidation is initiated when oxidising agents, such as 
free radicals, react with and remove hydrogen (H) atoms from PUFAs. This results in the 
formation of carbon-centred radicals. In an oxidation reaction with oxygen (O2) carbon-centred 
radicals form peroxyl radicals and hydroperoxides which are then reduced to form reactive 
isoprostanes and aldehyde by-products (Marnett, 1999) (Figure 13). Malondialdehyde (MDA) is 
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one such reactive by-product that is routinely used as a biomarker for lipid peroxidation (Janero, 
1990).  
2.5.2.2  Protocol 
To investigate the AAAgNP-mediated generation of ROS, MDA levels were measured using the 
thiobarbituric acid reactive substances (TBARS) assay.  
 
Figure 14: The reaction of malondialdehyde with thiobarbituric acid. 
Briefly, the following was added to a set of test tubes: 200µl of 2% H3PO4, 400µl of 7% H3PO4, 
400µl of thiobarbituric acid (TBA)/butylated hydroxytoluene (BHT) solution and 200µl of 1M 
HCL. Following treatment of cells (50 000 cells/well) in a 6-well plate, supernatants were 
recovered. For test samples, 100µl of cell supernatant (in triplicate) was then added to each test 
tube. A positive control was prepared by adding 1µl of MDA to a test tube. All tubes were 
incubated in a water bath (100°C, 15min) and after cooling; butanol (1.5ml) was added to each 
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tube, vortexed for 10 seconds and allowed to separate into two distinct phases. Approximately 
800µl of the upper butanol phase was then transferred to 1.5ml tubes and centrifuged (840 x g, 
24°C; 6min). To a 96-well micotitre plate, 100µl of supernatant was transferred in six replicates 
and the absorbance read using a spectrophotometer (Bio-tek μQuant) at 532/600nm. One 
molecule of MDA reacts with two molecules of TBA to form a coloured product (Figure 14). 
The mean absorbance was divided by the extinction co-efficient (156mM
-1
) and results were 
expressed as µM concentrations. 
2.6  Analysis of apoptotic parameters 
2.6.1 Assessment of caspase activity 
2.6.1.1  Introduction 
As mentioned earlier, caspases form the engine of apoptosis. The cleavage of inactive caspases 
(zymogens) is necessary for their catalytic activity and subsequent execution of cell death. The 
caspase assay used in this study is a luminometric assay that determines the activity of caspases 
based on the cleavage of caspase-specific Luciferin substrates. The amount of light generated by 




Figure 15: Principle for the detection of caspase activity. 
2.6.1.2  Protocol 
Caspase-3/-7, -8 and -9 activities were detected with Caspase-Glo
®
 assays (Promega, Madison, 
USA). As per manufacturer’s protocol, Caspase-Glo
®
-3/-7, -8 and -9 reagents were reconstituted 
and added to wells (in six replicates) of an opaque 96-well microtitre plate (40µl of reagent per 
100µl of 10 000 cells/well). Samples were mixed and incubated in the dark (30min, RT). The 
luminescent signal was measured on a Modulus™ microplate luminometer (Turner Biosystems, 






2.6.2 Annexin-V Fluos assay 
2.6.2.1  Introduction 
To determine the mode of cell death, the annexin-V-Fluos kit (Roche) was used. This assay 
comprises of annexin-V and propidium iodide (PI) and relies on flow cytometry for analysis. An 
early stage characteristic of apoptotic cells is the externalisation of phosphatidyl serine (PS). 
Necrotic cells, however, are identified by the leakage of DNA. Therefore, the percentage of PS 
translocated cells and DNA leakage was measured to give an indication of the amount of cells 
undergoing apoptotic and necrotic cell death respectively. Annexin-V is a calcium dependent 
phospholipid binding protein with a high affinity for PS whereas PI stains DNA (Figure 16). 
Exploiting these two components allows for the differentiation of apoptotic and necrotic cells. 
Annexin-V is conjugated to the fluorochrome fluorescein isothiocyanate (FITC). When analysed 
flow cytometrically, cells with externalized PS fluoresce green (excitation-488nm; emission-







Figure 16: The use of annexin-V and propidium iodide for the analysis of apoptotic and necrotic 
cells. 
2.6.2.2  Protocol 
To each flow cytometry tube, 100µl of staining buffer, 100µl of annexin-V-Fluos labelling 
solution (annexin-V: PI: staining buffer (1:1:50 vol/vol/vol)) and 100µl of cell suspension was 
added, and incubated in the dark (15min, RT). Samples were analysed on a FACS Calibur (BD 
Biosciences) flow cytometer. Data were analysed using CellQuest PRO v4.02 software (BD 
Biosciences). Cells were gated to exclude cellular debris using FlowJo v7.1 software (Tree Star, 
Inc). Approximately 50 000 events were analysed for apoptotic (annexin-V +ve, PI -ve), necrotic 
(annexin-V +ve, PI +ve) and live cells (annexin-V -ve, PI -ve). The results were expressed as 





2.6.3 JC-1 Mitoscreen assay 
2.6.3.1  Introduction 
Energy that is produced during oxidative phosphorylation is stored across the mt membrane as 
negative electrochemical potential. In this state the membrane is referred to as being polarised. 
Depolarisation of mt membrane occurs when there is a collapse in electrochemical potential. Mt 
depolarisation is observed as a crucial early event in apoptosis. The BD™ MitoScreen kit (BD 
Biosciences) was used to assess mt membrane potential (∆Ψ). J-aggregate-forming cationic dye 
(JC-1) is a lipophilic fluorochrome that is sensitive to ∆Ψ. This dye exists in a monomeric (at 
low concentration) as well as an aggregated form (at high concentration), both of which emit 
fluorescence in the green spectral region. When incubated with live cells, the fluorochrome 
penetrates the cell membrane (in its monomeric form) and is taken up by the mt. This process is 
mediated by ∆Ψ. The accumulation of JC-1 monomers inside the mt membrane leads to 
aggregation of the dye, which results in a spectral shift and the emission of red fluorescence 
(excitation-488nm; emissiom-590nm). When mt are depolarised, JC-1 remains in the cytoplasm 
as monomers and no spectral shift is seen (green fluorescent emission: excitation-488nm; 




Figure 17: Distinction between mitochondrial membrane polarisation and depolarisation. 
2.6.3.2  Protocol 
J-aggregate-forming cationic dye working solution was prepared (JC-1; 1x JC-1 wash buffer 
(1:50 vol/vol)) and 100µl added to each flow cytometry tube, followed by 100µl of cell 
suspension. Tubes were incubated at 37°C with 5% CO2 for 15min, after which 100μl of 1x JC-1 
wash buffer was added. Approximately 50 000 events were analysed for mt depolarisation. A 
FACS Calibur (BD Biosciences) flow cytometer was used. Data were analysed using CellQuest 
PRO v4.02 software (BD Biosciences). Cells were gated to exclude cellular debris using FlowJo 






2.6.4 Comet assay 
2.6.4.1  Introduction 
In mt-mediated apoptosis, a group of proteins are released from mt downstream of the apoptotic 
cascade that is responsible for the cleavage or fragmentation of DNA, an end stage feature of 
apoptosis. The comet assay or otherwise known as single cell gel electrophoresis (SCGE) is a 
simple procedure that detects DNA strand breaks and is used in genotoxicity testing. In this 
assay, cells are embedded on a microscopic slide with agarose and lysed with a high salt and 
detergent solution. The result is the formation of nucleoids that contain supercoiled DNA. When 
subjected to an electric field at high pH, loops of supercoiled DNA that contain breaks resemble 
comets following migration toward the anode (Collins, 2004). The application of the 
intercalating agent, ethidium bromide (EtBr), allows for the visualisation of comet tails using a 
fluorescent microscope. Comet tail lengths reflect the extent of DNA damage.  
2.6.4.2  Protocol 
The comet assay was used to determine DNA fragmentation in the AAAgNP treated lung cells. 
Briefly, three slides per sample were prepared with a first layer containing 400µl of 1% low 
melting point agarose (LMPA, 37°C), a second layer of 25µl of cells from each sample with 
175µl 0.5%  LMPA (37°C) and a third layer containing 200µl of 1% LMPA (37°C). Cover slips 
were removed and slides were subjected to lysis (4°C, 1hr, protected from light) by being 
submerged in cells lysis buffer (2.5M NaCl, 100mM EDTA, 1% Triton X-100, 10mM Tris (pH 
10) and 10% DMSO). The slides were equilibrated in electrophoresis buffer (300mM NaOH, 
1mM Na2EDTA, pH 13; 20min) then electrophoresced (300mA, 25V, 35min) after which slides 
were washed three times (0.4M Tris, pH 7.4; 5min) and finally stained with 40µl EtBr. Cover 
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slips were placed onto slides and maintained overnight at 4°C. Slides were viewed using a 
fluorescent microscope (Olympus IXSI inverted microscope/510-560nm excitation and 590nm 
emission wavelengths). Images were captured and comet tails of 50 cells were measured using 
Life Science-Soft Imaging System (analySIS
®
 v5). The results were expressed as mean tail 
length in μm. 
2.6.5 CD95 extracellular staining 
2.6.5.1  Introduction 
The extrinsic apoptotic pathway is mediated by cell surface death receptors. CD95 (Fas receptor) 
is one such receptor whose expression varies in different pathologies. Binding of Fas-L to CD95 
initiates a cascade that leads to the activation of initiator caspase-8 (Figure 18). The expression 
of CD95 was determined by a cell surface staining assay. Treating cells with an antibody, against 
CD95, conjugated to FITC allows for the detection of cells expressing CD95 by virtue of 




Figure 18: CD95 death receptor-ligand binding and the activation of caspase-8.  
2.6.5.2  Protocol 
Briefly, 100µl of 0.1M PBS and 1µl of FITC conjugated mouse anti-human CD95 antibody (BD 
Pharmingen, 555673) was added to 100µl of cell suspension. Reaction mixture was incubated in 
the dark for 15min at RT, thereafter run on a FACS Calibur. Data were analysed using CellQuest 
PRO v4.02 software. Cells were gated to exclude cellular debris using FlowJo v7.1 software. The 




2.6.6 Smac/DIABLO intracellular staining 
2.6.6.1  Introduction 
Amongst various pro-apoptotic proteins that are released from the mt, is smac/DIABLO. This 
protein counteracts the caspase inhibitory effects of IAPs. Similar to CD95 analysis, intracellular 
levels of smac/DIABLO were assessed by intracellular staining using flow cytometry. Anti 
smac/DIABLO conjugated to a fluorochrome - allophycocyanin (APC: excitation-650nm; 
emission-660nm) is added to a suspension of cells after treatment with a permeabilising agent. 
When analysed on a flow cytometer, the amount of fluorescence emitted is proportional to the 
level of smac/DIABLO.  
2.6.2.2. Protocol 
Cells were rendered permeable by incubation in Fix and Perm medium A (Caltag) (15min in the 
dark), after which they were treated with Fix and Perm medium B (Caltag) containing 
monoclonal anti-smac/DIABLO primary antibody (smac/DIABLO, ab110291) (1:500; 30min, 
RT). After washing, cells were re-suspended in medium B containing APC conjugated anti-
mouse secondary antibody (Thermo Scientific, 31430) (1:100; 15min, RT) protected from light. 
Cells were then washed, re-suspended in 0.1M PBS and run on a FACS Calibur. Data were 
analysed using CellQuest PRO v4.02 software. Cells were gated to exclude cellular debris using 






2.6.7 Western blotting 
2.6.7.1  Introduction 
2.6.7.1.1 Protein isolation 
Following the isolation of protein from cells, crude extracts were quantified and standardised 
using the bicinchoninic acid (BCA) assay. Proteins and peptides do not absorb light in the visible 
region of the spectrum. However, when treated with an alkaline solution of Cu
2+
/tartrate 
complex, a purple colour develops due to the complexing of the Cu
2+ 
ions by peptide bonds. This 
colour reaction is characteristic of the biuret reaction in which a reduction of cupric (Cu
2+
) ion to 
cuprous (Cu
+
) ion by protein in an alkaline medium occurs. The Cu
+ 
ion is then detected by a 
reaction with BCA to produce an intense purple colour that absorbs maximally at 562nm (Figure 
20). The intensity of the colour produced is proportional to the number of peptides bonds 
participating in the reaction. 
 
Figure 19: Mechanism of protein detection in the bicinchoninic acid assay. 
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2.6.7.1.2 Electrophoresis and transfer 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) is a technique that 
is extensively employed to separate proteins. Polyacrylamide is a matrix that is formed by the 
copolymerisation of monomers of acrylamide and bis-acrylamide (“bis,” N,N'-methylene-
bisacrylamide). A strength of polyacrylamide is that it is inert, thus will not interact with proteins 
as they migrate through. Sodium dodecyl sulphate is an anionic detergent which denatures 
proteins by forming micelles around the polypeptide. Sodium dodecyl sulphate confers a uniform 
negative charge to the polypeptide. Since differences in charge and shape are eliminated as 
variables, separation in SDS-PAGE is based on the molecular weights of proteins. Following 
protein standardisation, samples are prepared with sample buffer (which contains SDS; a tracker 
dye – bromophenol blue; β-mercaptoethanol – to unfold tertiary protein structures by reducing 
disulfide bridges; and glycerol – adds density to the sample) before being electrophoresced on 
SDS-PAGE gels. These gels comprise of a stacking layer and a separating layer. Once 
electrophoresced, protein bands are transferred to nitrocellulose membranes via electroblotting 
(Figure 20). This involves the sandwiching of the gel and nitrocellulose membrane by fibre pads. 





Figure 20: Set up of components for electroblotting.  
2.6.7.1.3 Immuno-blotting 
Proteins are analysed on the nitrocellulose membrane using antigen-specific antibodies. 
Subsequent to blocking of remaining hydrophobic binding sites on the membrane with a protein 
solution, membranes are incubated with primary antibody against the protein of interest. A 
second incubation with horseradish peroxidase (HRP)-conjugated secondary antibody, directed 
against the primary antibody, permits the visualisation of the interaction between primary 
antibody and the protein of interest. Horseradish peroxidase, in the presence of H2O2, oxidises 
luminol (chemiluminescent substrate) with concomitant generation of light. The use of a 
chemical enhancer results in a 1000-fold increase in the intensity of light, which is detected by a 
photographic film. The intensity of light produced is proportional to the expression of the protein 




Figure 21: Antibody-antigen reaction for the detection of chemiluminescence.  
2.6.7.2  Protocol 
Cytobuster™ reagent (Novagen) supplemented with protease and phosphatase inhibitors (Roche, 
05892791001 and 04906837001 respectively) was used for protein isolation. Cytobuster (200μl) 
was added to the cells (4°C, 10min) and centrifuged (180 x g; 4°C, 10min) to obtain a crude 
protein extract. Protein samples were quantified using the BCA assay and standardised to 
1mg/ml. Samples (25μl) were electrophoresced on 7.5% SDS-PAGE gels and thereafter 
transferred to nitrocellulose membranes. Membranes were blocked with 3% bovine serum 
albumin (BSA) in Tris buffer saline (20mM Tris-HCl (pH 7.4), 500mM NaCl and 0,01% Tween 
20 (TBST)) for 1h, and incubated with primary antibody (p53, ab26; bax, ab5714; PARP-1, 
ab110915; smac/DIABLO, ab110291 and β-actin, ab8226; 1:1,000) in 1% BSA in TBST at 4°C 
overnight. Membranes were then washed thrice (10ml TBST, 15min) and treated with HRP-
conjugated secondary antibody (mouse, ab97046; 1:2,000) (1h, RT). Membranes were washed 
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again 3 times (TBST, 15min) and immunoreactivity was detected by the LumiGLO
®
 
chemiluminescent substrate system (KPL) with the Uvitech Image Documentation System 
(UViTech Alliance 2.7). Protein bands were analysed with the UViBand Advanced Image 
Analysis software (UViTech v12.14). The results were expressed as mean relative band intensity 
(RBI). 
2.6.8 Quantitative-polymerase chain reaction 
2.6.8.1  Introduction 
PCR is a molecular technique, homologous to cellular DNA replication, which is used to amplify 
a precise region of DNA from a template starting material. Two oligonucleotide primers 
complementary to the sites flanking the target region are chemically synthesised. The primers 
attach to the 3’ ends of each DNA template strand after which DNA polymerase incorporates 
deoxynucleotide triphosphates (dNTPs) in a stepwise manner to the 3’ ends of the primers.  
There are three defined steps in PCR: 1) denaturation, 2) annealing and 3) extension. 
Denaturation involves the separation, usually above 90°C, of double stranded (ds) DNA into two 
single stranded (ss) DNA template strands for accessibility of the target region. In the annealing 
step, the temperature is dropped to allow for the hybridisation of oligonucleotide primers to 
complementary sites flanking the target region. Finally, extension entails the synthesis of DNA 
(addition of dNTPs) at the free 3’ hydroxyl end of the primers by thermostable Taq DNA 
polymerase. This cycle is repeated for 30-40 times, and the result is an exponential amplification 




Figure 22: Exponential amplification of target DNA in polymerase chain reaction. 
Although conventional PCR successfully achieves the amplification of DNA, it is not 
quantitative. Being able to quantify the DNA template or starting material is important in 
pathologies where a protein may be expressed abnormally. Quantitative-polymerase chain 
reaction is a technique that enables one to determine the amount of a target gene in a sample. 
48 
 
RNA is first isolated from cells and then reverse transcribed to ss complementary (c) DNA. 
cDNA is then used as the starting material for Q-PCR. The cycling steps of Q-PCR are similar to 
conventional PCR. Quantification of DNA is made possible by including a DNA-binding dye 
called SYBR Green in the reaction. SYBR Green binds to dsDNA amplicons proportionally and 
the fluorescence is detected after excitation. A curve is plotted with fluorescent emission over 
time from which the initial amount of DNA in each sample is obtained. A threshold is set at a 
constant point of exponential increase in the curves and the cycle time (Ct) value for each sample 
is determined. Along with the gene of interest, samples are analysed for expression of a house 
keeping gene, and the amount of target DNA is reported relative to the amount of the house 
keeping gene for each sample.  
2.6.8.2  Protocol 
2.6.8.2.1 RNA isolation 
Total RNA was extracted using Trizol. Briefly, 500µl of Trizol was added to 500μl of cell 
suspension (50 000 in 0.1M PBS) in 1.5ml tubes. After 5min of incubation at RT, cells with 
Trizol were frozen (-80°C) for 1h. Subsequently, 100μl of chloroform was added to the thawed 
samples with vigorous mixing and thereafter incubation (3min, RT). Tubes were then subjected 
to centrifugation (12 000 x g, 15min, 4°C) following which the aqueous layer was transferred to 
a new 1.5ml tube on ice. To this, 250μl of isopropanol was added and incubated (-80°C, 1h). 
Tubes were centrifuged (12 400 x g, 20min, 4°C) and pellets containing total RNA were 
recovered. Cold ethanol (75%) was then used to wash pellets (7,400 x g, 15min, 4°C). Ethanol 
was discarded and RNA pellets left to air dry (10min) before being resuspended in 15μl of 
RNase-free water. After incubation (3min, RT) RNA samples were mixed well, quantified 
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spectrophotometrically and standardised to 100ng/μl with RNase-free water. Samples were 
stored at -80°C for further use. 
2.6.8.2.2 cDNA synthesis 
RNA was reverse transcribed to cDNA as per manufacturers’ guidelines using the RT
2
 First 
Strand Kit (SA Biosciences™). Firstly, genomic DNA elimination mixture (10μl) was prepared 
with 2μl (200ng) of total RNA, 2μl of 5X gDNA elimination buffer and 6μl of RNase-free water. 
Secondly, reverse transcriptase cocktail (10μl) was prepared with 4μl of reverse transcriptase 
buffer 3, 1μl of primer and external control mix, 2μl of reverse transcriptase enzyme mix and 3μl 
of RNase-free water. For the cDNA synthesis reaction, a 20μl reaction containing 10μl each of 
genomic DNA elimination buffer and reverse transcriptase cocktail for each sample was 
prepared and subjected to incubation at 42°C (15min) followed by heating at 95°C (5min) 
(GeneAmp® PCR System 9700, Applied Biosciences). Subsequently, 80μl of RNase-free water 
was added to each reaction mixture and stored at -70°C for further use. 
2.6.8.2.3 Quantitative-polymerase chain reaction 
The mRNA expression of p53 and bax were investigated using Q-PCR. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as the house keeping gene. Primer sequences were 
obtained from Inqaba Biotechnologies: p53 (sense: 5’CCACCATCCACTACAACTACAT’3, 
antisense: 5’CAAACACGGACAGGACCC‘3) bax (sense: 
5’ATGCGTCCACCAAGAAGCTGAG‘3, antisense: 5’GACTGCCGTTGAAGTTGACCCC‘3) 




The iQ™ SYBR Green Supermix (cat. 170-8880, Biorad) was used for Q-PCR.  Amplification 
proceeded in a 25µl reaction consisting of: 12.5μl of the iQ™ SYBR Green Supermix, 2μl of 
cDNA, 1μl of the primer set and 8.5μl of RNase-free water. Cycling conditions were: initial 
denaturation (95°C, 15min), 40 cycles of denaturation (95°C, 30s), annealing (55°C, 30s) and 
extension (72°C, 30s) followed by final extension (72°C for 7min) (Chromo4™ R-T PCR 
Detector, BIORAD). 
For analysis of results, the method described by Livak and Schmittgen (2001) was used. Results 
are expressed as 2
-∆∆Ct
. In order to determine fold changes in the expression of genes between 
samples, the Ct values for the control samples was set at 1. Differences in Ct values between 
gene of interest and housekeeping gene for test samples and controls is represented by ∆∆Ct, 
which is expressed as fold change (2
-∆∆Ct
) (Livak and Schmittgen, 2001). 
Quantitative-polymerase chain reaction products were verified using electrophoresis (120V, 
30min) on a 2% agarose gel supplemented with 0.5mg/ml EtBr. Bands were visualised using the 
Uvitech Image Documentation System (UViTech Alliance 2.7). 
2.7  Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5.00 software package 
(GraphPad PRISM
®
) and Microsoft excel 2007. Data are expressed as mean ± standard error of 
the mean (sem). Comparisons were made using the unpaired Student t-tests. Statistical 







3.1  Cell viability 
3.1.1 MTT assay 
The toxicity of AAAgNP to A549 cells was determined using the MTT assay. A dose-dependent 
decline in cell viability was observed using AAAgNP concentrations in the range 0 to 75μg/ml for 
6h (95% Cl=31.96 to 57.72) (Figure 23). An IC50 value of 43μg/ml was obtained and used in all 
subsequent assays. 
 
Figure 23: A dose-dependent decline in A549 cell viability after AAAgNP treatment. 
3.1.2 ATP assay 
Cellular ATP levels were assessed using the CellTire Glo
™
 assay. AAAgNP significantly reduced 
ATP levels with a 2.5-fold decrease (350 000±1500RLU; 95% CL=330 000 to 370 000) 
52 
 
compared to the control (990 000±40 000RLU; 95% Cl=480 000 to 1 500 000; p=0.0040) 
(Figure 24). 
 
Figure 24: ATP levels in control and AAAgNP treated A549 cells (p=0.0040). RLU: relative light 
units. 
3.2  Oxidative stress 
3.2.1 Glutathione assay 
Glutathione concentrations were measured using the GSH-Glo™ Glutatione assay as a marker 
for intracellular anti-oxidant capacity. The concentration of GSH was higher in untreated cells 
(15±1.3µM) compared to AAAgNP treated cells (12±0.24µM, 95% Cl=-1.0 to 6.2; p=0.1184) 




Figure 25: Glutathione levels in AAAgNP treated cells (p=0.1184). 
3.2.2 Lipid peroxidation 
Additionally, lipid peroxidation (MDA-measured by the TBARS assay) was significantly 5-fold 
higher in cells exposed to AAAgNP (0.16±0.023μM) compared to controls (0.032±0.016μM, 95% 
Cl=-0.21 to -0.049; p=0.0098) (Figure 26).  
 
Figure 26: Malondialdehyde (lipid peroxidation) levels in AAAgNP treated cells (p=0.0098).  
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3.3  Analysis of apoptotic parameters 
3.3.1 Analysis of caspases  
Caspase-Glo
®
 assays were used to determine caspase activity. AAAgNP significantly increased the 
activities of caspase-3/-7 (1.7-fold, 95% Cl=-1 000 000 to -260 000; p=0.0180) and -9 (1.4-fold, 
95% Cl=-610 000 to -220 000; p=0.0117) compared to the control. The activity of caspase-8 
however was significantly decreased by AAAgNP compared to untreated cells (2.5-fold, 95% 
Cl=550 000 to 840 000; p=0.0024) (Table 1). Bar graphs are shown in Appendix C (1-3). 
Table 1: Caspase activity in AAAgNP treated cells. RLU: relative light units. 
 CONTROL AAAgNP  
 Mean RLU ± sem Mean RLU ± sem p value 
CASPASE-3/-7 920 000±4 000 1 600 000±86 000 0.0180* 
CASPASE-8 1 200 000±26 000 460 000±23 000 0.0024** 
CASPASE-9 920 000 ± 33 000 1 300 000±31 000 0.0117* 
 
3.3.2 Annexin-V Fluos assay 
The annexin-V-Fluos assay was used to determine the mode of cell death. Treatment with 
AAAgNP significantly increased PS translocation in A549 cells compared to the control 
(57±0.59% vs. 10±0.84%, 95% Cl= -50 to -43; p<0.0001) (Figure 27/28). Furthermore, the 
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percentage of necrotic cells were also significantly higher in AAAgNP treated cells (17±0.79% vs. 
control: 4.6±0.70%, 95% Cl= -16 to -9.2; p<0.0001) (Figure 27/28).  
 
Figure 27: Percentages of apoptotic and necrotic A549 cells (p<0.0001). 
 
Figure 28: Dot plots showing spectral shifts for flow cytometric analysis of annexin-V and 
propidium iodide staining in A) control cells and B) cells treated with AAAgNP. 
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3.3.3 JC-1 Mitoscreen assay 
The apoptosis inducing potential of AAAgNP was further verified in disrupting mt ∆Ψ using the 
BD™ MitoScreen kit. The treated cells had significantly higher mt depolarisation compared to 
untreated cells (77±0.88% vs. 23±1.8%, 95% Cl= 44 to 57; p<0.0001) (Figure 29/30). 
 




Figure 30: Spectral shift in JC-1 dye for the analysis of mitochondrial membrane integrity. Dots 
plats obtained from flow cytometric analysis of A) control and B) treated cells. 
3.3.4 Comet assay 
The genotoxic effect of AAAgNP was assessed with the comet assay. Comet tail lengths were 
measured as an indication of DNA fragmentation. Silver nanoparticles of AA were significantly 
genotoxic to A549 cells as noted by the increased DNA fragmentation (Figure 31). Comet tail 
lengths were significantly longer in treated (90±1.3μm) compared to untreated cells (20±0.71μm, 




Figure 31: DNA fragmentation was markedly higher in cells exposed to AAAgNP (B) than 
untreated control cells (A) (p<0.0001) (100x). 
3.3.5 CD95 
The expression of CD95 death receptor, assessed by extracellular staining using flow cytometry, 
was significantly down regulated (2-fold; 2.8±0.58% vs. control: 5±0.44%, 95% Cl=0.13 to 4.2; 





3.3.6 Smac/DIABLO intracellular staining 
In contrast, flow cytometric intracellular staining revealed that AAAgNP significantly increased 
the expression of the pro-apoptotic smac/DIABLO (29±0.32%) compared to the control 
(18±0.66%, 95% Cl=-13 to -8.5; p<0.0001) (Table 2).  
Table 2: Surface expression of CD95 and intracellular smac/DIABLO in A549 cells treated with 
AAAgNP as determined flow cytometrically. 
 CONTROL AAAgNP  
 Mean % ± sem Mean % ± sem p value 
FITC +ve (CD95) 5±0.44 2.8±0.58   0.0416* 
APC +ve (smac/DIABLO) 18±0.66 29±0.32 <0.0001*** 
 
3.3.7 Western blot analysis 
The expression of selected apoptotic proteins and validation of flow cytometric intracellular 
stained smac/DIABLO was determined by western blotting. The expression of p53 was observed 
to be significantly higher post AAAgNP exposure (1.0±0.018RBI vs. control: 0.82±0.045RBI, 
95% Cl= -0.42 to -0.00037; p=0.0498). A significant increase in the levels of PARP-1 was noted 
after AAAgNP treatment (3.5±0.069RBI vs. control: 3.1±0.0043RBI, 95% Cl= -0.65 to -0.058; 
p=0.0359). Evaluation of bax showed higher levels of the protein in cells that were treated with 
AAAgNP (3.4±0.11RBI) compared to untreated cells (2.1±0.047RBI, 95% Cl= -1.9 to -0.81; 
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p=0.0083). Highly significant differences were seen in the expression of smac/DIABLO between 
experimental and control cells. Cells treated with AAAgNP presented with a 4.1-fold greater band 
intensity (1.1±0.045RBI vs. control: 0.27±0.010RBI, 95% Cl= -0.99 to -0.59; p=0.0033) (Figure 
32). 
 
Figure 32: Western blot images and band intensity graphs for the expression of A) p53 
(p=0.0498) B) bax (p=0.0083) C) PARP-1 (p=0.0359) and D) smac/DIABLO (p=0.0033). 
3.3.8 Quantitative-polymerase chain reaction 
The expression of p53 and bax mRNA was investigated using Q-PCR. Consistent with western 
blotting data that showed an increase in the expression of p53 and bax proteins, mRNA levels for 
both proteins were upregulated. A 6-fold (95% CI= -7.267 to -2.733; p=0.0036) and 5-fold (95% 
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CI= -6.267 to -1.733; p=0.0080) increase in mRNA expression were observed for p53 and bax 
respectively in AAAgNP treated cells (Figure 33).  
 
Figure 33: Fold change graphs for the mRNA expression of A) p53 (p=0.0036) and B) bax 












Several pathological syndromes such as liver failure, stroke or heart attack are associated with an 
abrupt death of tissue or organs as a result of apoptotic dysregulation. Conversely, the survival 
and build up of abnormal cells, in the case of unsuitably low apoptotic rates, may lead to 
tumourigenesis (Fischer and Schulze-Osthoff, 2005). Apoptosis, a programmed mechanism of 
cell death, is the outcome of a succession of precisely regulated events, which are commonly 
altered in cancerous cells (Kasibhatla and Tseng, 2003). In essence, tumour cells have the ability 
to evade the apoptotic cascade, which represents a notable causative factor for the development 
and progression of cancer – uncontrolled cell proliferation.  
Plant extracts are known to contain weak acids. Albizia adianthifolia possesses acids such as 
ethyl acetate and aurantiamide acetate (Tamokou Jde et al., 2012). Weak acids are known to 
disrupt mt function by depolarisation of the membrane, disruption of the ETC and decreased 
ATP production (Komen et al., 2007). The ability of weak acids to penetrate the mt membrane 
results in metabolic dysfunction; the TCA cycle, which occurs in the mt matrix, is responsible 
for the production of reducing equivalents required by oxidoreductases. Silver nanoparticles of 
AA caused a dose-dependent decrease in A549 cell viability as was observed by a decrease in 
formazan product (dependent on reducing equivalents and the function of oxidoreductases) 
(Figure 23). This may be due to the weak acids found in the AA extracts. Furthermore, NPs 
preferentially localise in mt and potentiate structural damage (Derfus et al., 2004; Xia et al., 
2006). Various studies have associated AgNP toxicity with mt damage (Carlson et al., 2008; Xia 
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et al., 2008). This could further contribute to the anti-proliferative properties of AAAgNP as 
observed in our study. 
The signal transduction of apoptosis involves a cascade of initiator and executioner caspases, 
which form the engine of apoptosis. Caspases are a family of aspartate-specific cysteinyl 
proteases that are produced as catalytically inactive zymogens in cells (Chai et al., 2000).  
Executioner caspases-3 and -7 are a subset that cleaves specific substrates leading to alteration 
changes linked with apoptosis viz. chromatin condensation, DNA fragmentation, blebbing of 
plasma membrane, cell shrinkage and ultimately cell death (Kasibhatla and Tseng, 2003). 
Initiator caspses-8 and -9 are responsible for the activation of executioner caspases. AAAgNP 
significantly up regulated the activities of caspases-3/-7 and -9 (Table 1). Furthermore AAAgNP 
increased DNA fragmentation (Figure 31)-an end stage characteristic of apoptosis. In response to 
this DNA damage, the nuclear enzyme PARP-1 catalyzes the transfer of NAD
+
 to a specific set 
of nuclear substrates for the repair of DNA damage (Shall and de Murcia, 2000). During 
apoptosis, PARP-1 is cleaved, by executioner caspases-3/-7, to a 24kDa DNA binding domain 
and an 89kDa fragment containing catalytic activity. The silver nanoparticles of AA were 
responsible for the cleavage of PARP-1 as evidenced by the significant increased expression of 
24kDa fragment compared to untreated control cells (Figure 32C).  
A biochemical feature associated with apoptosis is the expression of cell surface markers. The 
externalisation of PS (a transmembrane glycoprotein of the phospholipid bilayer) signals for 
early phagocytosis of apoptotic cells with minimal compromise to adjacent and surrounding 
tissue (Bratton et al., 1997). A significant increase in PS externalisation occurred in A549 cells 
treated with AAAgNP (Figure 27/28). 
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Mitochondria play an important role in apoptosis, via the intrinsic apoptotic program. An initial 
crucial step for activation of the intrinsic apoptotic pathway is the depolarisation of the mt 
membrane. Depolarised mt is as a result of the formation of mt PT pores (Hirsch et al., 1997). 
Mitochondrial PT has been associated with various metabolic consequences such as halted 
functioning of the ETC with associated elevation in ROS and decreased production of cellular 
ATP (Wang, 2001). Bax, a pro-apoptotic protein of the Bcl-2 family, translocates from the 
cytosol to the outer mt membrane during apoptosis where it interacts with lipids and induces mt 
PT pores. A significant increase in mt depolarisation was observed after AAAgNP treatment 
(Figure 29/30), with an accompanying decrease in ATP concentration (Figure 24). As 
mentioned, weak acids from AA may cause mt dysfunction, as they penetrate the mt membrane. 
The high levels of bax mRNA (Figure 33B) and its protein expression (Figure 32B), high mt 
depolarisation and decreased ATP suggests that AAAgNP induced cellular apoptosis in these 
cancerous lung cells via the intrinsic mt-mediated apoptotic pathway. 
Silver has a high affinity for thiol (-SH) groups (Navarro et al., 2008). In this study, the levels of 
cysteine-rich GSH were decreased (Figure 25) whilst lipid peroxidation was significantly 
elevated by AAAgNP (Figure 26). This oxidant/anti-oxidant imbalance has previously been 
documented as an apoptotic mechanism by AgNP-mediated cytotoxicity (Ueda et al., 2002; 
Foldbjerg et al., 2009). The regulation of GSH/GSSG ensures that cells are not rendered 
vulnerable to oxidative damage as a result of GSH deficiency. Notably, the imbalance of GSH is 
strongly associated with pathologies such as HIV, neurodegenerative disorders and cancer 
(Townsend et al., 2003). Malondialdehyde, a marker for lipid peroxidation due to ROS attack of 
PUFAs, is known to react with nucleotide bases in DNA and form adducts; an implication for 
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mutagenesis and possibly cancer (Del Rio et al., 2005). Studies have linked high MDA levels 
with aetiology of lung cancer (Gonenc et al., 2001).  
The extrinsic apoptotic pathway is mediated by death receptors, which include CD95, TNF-R1 
and TRAIL-R1/R2. These death receptors contain DDs and upon ligand binding, recruit adapter 
FADD via the DD. Adapter proteins bind to death effector domain-containing caspases-8 giving 
rise to the formation DISC. Death inducing signalling complex initiates caspase-8 activation, 
which can directly cleave and activate effector caspases (Fischer and Schulze-Osthoff, 2005). 
Our results show that CD95 expression (Table 2) and caspase-8 activity (Table 1) were 
significantly decreased by AAAgNP. It must be understood that even though initiator caspase-8 
activity was reduced, the activities of executioner caspases-3 and -7 were still increased. This is 
as a result of elevated initiator caspase-9 activity together with increased levels of 
smac/DIABLO which is responsible for the activation of caspases-3 and -7. The extracts of AA 
are rich in saponins, which promotes rapid entry of the AAAgNP into the cells resulting in mt-
mediated intrinsic apoptosis. A well characterised biological action of saponins is their ability to 
induce cell membrane permeabilisation (Hostettmann and Martson, 1995). Decreased ATP 
concentrations and increased MDA as a result ROS may be due to disruptions in the mt 
respiratory chain.  
Several pro-apoptotic molecules are released from the mt during apoptosis. In the presence of 
ATP, mt released cytochrome c associates with Apaf-1 in the cytosol inducing its 
oligomerisation. An apoptosome is then formed with the oligomeric Apaf-1 complex and 
procaspase-9, inducing the activation of caspase-9, which in turn activates effector caspases-3 
and -7 (Chai et al., 2000). An interesting finding in this study was that although ATP levels were 
reduced post AAAgNP treatment, the activity of caspase-9 was still elevated (Table 1).  
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A class of molecules involved in the regulation of apoptosis is IAP proteins. Inhibitor of 
apoptosis proteins avert cell death by suppressing the activity of caspases. X-linked mammalian 
IAP is the most well characterised member of IAPs (Fischer and Schulze-Osthoff, 2005). The 
ability of IAPs to act as endogenous suppressors of procaspase activation is attributed to the 
presence of domains referred to as BIR domains. In particular, BIR3 and a region adjacent to 
BIR2 are responsible for the inhibition of caspases-9, and -3 and -7 respectively. Smac/DIABLO, 
a mt protein, is able to abolish the inhibitory effects of XIAP (Chai et al., 2000). Both 
smac/DIABLO and caspases-3,-7 and -9 contain IAP-binding motifs (IMB) that fit into the BIR 
domains of XIAP. Thus, smac/DIABLO is able to relieve inhibition by replacing and releasing 
caspases-3, -7 and -9 from the XIAP inhibitory complex (Chai et al., 2000; Fischer and Schulze-
Osthoff, 2005). In our study, we postulated that AAAgNP released smac/DIABLO from the mt. 
The increased intracellular (A549) staining (Table 2) and expression of smac/DIABLO by 
western blotting (Figure 32D) confirmed that AAAgNP did induce the release of this protein from 
the mt of the A549 cells.  
The p53 (tumour suppressor/transcription) protein mediates a range of anti-proliferative 
processes in response to different stress stimuli. The p53 protein directly activates apoptosis by 
promoting the release of bax (Miyashita et al., 1994) and inducing executioner caspase activity 
(MacLachlan and El-Deiry, 2002) Also, p53 is involved in cell death independent of its 
transcriptional activity. This is attributed to the BH3-like activity of p53. Upon translocation to 
the mt, p53 neutralises the anti-apoptotic function of Bcl-2, directly activates bax and interferes 
with mt integrity and function leading to the release of pro-apoptotic molecules and the 
generation of ROS (Hwang et al., 2001). Our study clearly shows the increased expression of 
p53 by AAAgNP in the A549 cells (Figure 32A) and this correlated with an increase in mt 
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depolarisation and ROS. Furthermore, the levels of mRNA for p53 were upregulated, which 
validates the increased p53 protein expression (Figure 33A). 
A summary of the potential target sites in the apoptotic cascade, by AAAgNP is illustrated in 
figure 34.  
 
Figure 34: Schematic overview of the apoptotic pathways leading to cell death. Potential sites 





Mortality and morbidity due to lung cancer is increasing globally. Current cancer therapies are 
costly, and are associated with a number of adverse effects. Furthermore, individuals receiving 
treatments for other ailments, such as AIDS (ARV therapy), incur added costs. This emphasises 
the need for the development of cost-effective and safer therapies. This study was conducted to 
determine the anti-cancer effects of a novel AgNP synthesised from leaf extracts of AA on the 
A549 human lung carcinoma cell line. 
Silver nanoparticles of AA were found to possess potent pro-apoptotic potential. We have 
shown, mechanistically, that AAAgNP activates the intrinsic mt-mediated apoptotic pathway in 
A549 lung carcinoma cells. The effects of AA leaf extract and AgNPs separately on the A549 
cells have not been investigated in this study. This creates an avenue for future research. 
The findings of this study suggest the potential for AAAgNP in drug development against cancer. 
None the less, further studies need to be conducted to ascertain if the effects of AAAgNP are 
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Figure 1: A) Aqueous leaf extracts solution, B) silver nitrate solution and C) yellowish- brown 
colloidal solution of AAAgNP and UV-vis spectra of AAAgNP showing the surface Plasmon 













Figure 2: A) Transmission electron microscope micrograph of silver nanoparticles synthesised 















Figure 3: Illustration of Fourier transform infrared spectroscopy spectra of A) aqueous leaf 













Table 1: Raw data for the determination of IC50 using the cell viability (MTT) assay.  
AAAgNP concentration    Average absorbance %viability Log [AAAgNP] 
0    0.955 100.0  
2    0.938 98.3 0.30103 
4    0.872 91.3 0.60206 
8    0.819 85.7 0.90309 
10    0.738 77.3 1 
15    0.803 84.1 1.176091 
20    0.680 71.2 1.30103 
30    0.564 59.0 1.477121 
40    0.377 39.5 1.60206 
50    0.247 25.9 1.69897 
60    0.212 22.2 1.778151 











Figure 1: Caspase-3/-7 activity was significantly higher in cells exposed to AAAgNP compared to 
untreated cells (p=0.0180). 
2) 
 
Figure 2: The activity of caspase-8 was significantly reduced in cells exposed to AAAgNP 






















Figure 1: Extracellular staining-flow cytometry was used to evaluate the expression of CD95 
(Fas receptor). Three replicates were done for both treated (B1-B3) and untreated (A1-A3) cells. 









Figure 2: Levels of smac/DIABLO, a pro-apoptotic protein, were determined flow 
cytometrically using an intracellular staining assay. A significantly higher expression of 
smac/DIABLO was observed in A549 cells after treatment with AAAgNP (B1-B3) compared to 















Figure 1: Calibration curve using known concentrations of bovine serum albumin for the 
determination of protein concentration in samples using the bicinchoninic acid assay.  
2) 
Table 1: Standardisation of protein using the calibration curve for sodium dodecyl sulphide-
polyacrylamide gel electrophoresis. 
 Average absorbance Protein (mg/ml) C2 (mg/ml) V2 (μl) V1 (μl) 
Control 1.595 1.240276 1 100 80.62719 
Control 1.6425 1.274113 1 100 78.48597 
AAAgNP 1.4045 1.104573 1 100 90.5327 
AAAgNP 1.338 1.057202 1 100 94.58931 
 
 
y = 1.4038x - 0.1461 
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